Denosumab: An investigational drug for the management of postmenopausal osteoporosis

Biologics: Targets and Therapy

Volumn 2, Issue 4, 2008, Pages 645-653

  Michael Lewiecki, E ^a  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

AMG 162; Denosumab; OPG; Osteoporosis; RANKL; Treatment

Indexed keywords

EID: 77956361572     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Atkinson JE, Cranmer P, Saunders T, et al. 2005. Denosumab (AMG 162), a fully human RANKL antibody, increases bone mass and bone strength in cynomolgus monkeys. J Bone Miner Res, 20(Suppl 1):S294.
2. Autier P, Haentjens P, Bentin J, et al. 2000. Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int, 11:373-80.
3. Bekker, PJ, Holloway, D, Nakanishi, A, et al. 2001. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res, 16:348-60.
4. Bekker PJ, Holloway DL, Rasmussen AS, et al. 2004. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res, 19:1059-66.
5. Body JJ, Greipp P, Coleman RE, et al. 2003. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer, 97(3 Suppl):887-92.
6. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature, 423:337-42.
7. Bucay N, Sarosi I, Dunstan CR, et al. 1998. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev, 12:1260-8.
8. Burge R, Dawson-Hughes B, Solomon DH, et al. 2007. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. Journal of Bone and Mineral Research, 22:465-75.
9. Burgess TL, Qian Y, Kaufman S, et al. 1999. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol, 145:527-38.
10. Buxton EC, Yao W, Lane NE. 2004. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab, 89:3332-6.
11. Byrne FR, Morony S, Warmington K, et al. 2005. CD4BCD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut, 54:78-86.
12. Capparelli C, Morony S, Warmington K, et al. 2003. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res, 18:852-8.
13. Caro JJ, Ishak KJ, Huybrechts KF, et al. 2004. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int, 15:1003-8.
14. Center JR, Nguyen TV, Schneider D, et al. 1999. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet, 353:878-82.
15. Clowes JA, Riggs BL, Khosla S. 2005. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev, 208:207-27.
16. Cohen SB, Lewiecki EM, Liu Y, et al. 2005. Phase 2 study of denosumab (AMG 162) in postmenopausal women: subanalyses and supplemental safety. J Bone Miner Res, 20(Suppl 1):S295.
17. Collin-Osdoby P. 2004. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res, 95:1046-57.
18. Cooper C. 1997. The crippling consequences of fractures and their impact on quality of life. Am J Med, 103:12S-9S.
19. Cramer JA, Gold DT, Silverman SL, et al. 2007. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int, 18:1023-31.
20. Dougall WC, Glaccum M, Charrier K, et al. 1999. RANK is essential for osteoclast and lymph node development. Genes Dev, 13(18):2412-24.
21. Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. 2003. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest, 111:1221-30.
22. Feldstein A, Elmer PJ, Orwoll E, et al. 2003. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures-A gap in evidence-based practice guideline implementation. Arch Intern Med, 163:2165-72.
23. Ferrari SL, Pierroz D, Bonnet N, et al. 2007. A comparison of denosumab and alendronate in combination with PTH in ovariectomized knockin mice expressing humanized RANKL. J Bone Miner Res, 22(Suppl 1):S37.
24. Hofbauer LC, Khosla S, Dunstan CR, et al. 1999. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology, 140:4367-70.
25. Hofbauer LC, Schoppet, M. 2004. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA, 292:490-5.
26. Hofbauer LC, Zeitz U, Schoppet M, et al. 2007. RANK Ligand inhibition by denosumab prevents cortical bone loss in a murine model of glucocorticoid-induced osteoporosis. J Bone Miner Res, 22(Suppl 1):S4.
27. Hsu H, Lacey DL, Dunstan CR, et al. 1999. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A, 96:3540-5.
28. Johnell O, Kanis JA, Oden A, et al. 2004. Fracture risk following an osteoporotic fracture. Osteoporos Int, 15:175-9.
29. Josien R, Wong BR, Li HL, et al. 1999. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol, 162:2562-8.
30. Kanis JA, Borgstrom F, De Laet C, et al. 2005. Assessment of fracture risk. Osteoporos Int, 16:581-9.
31. Klibanski A, Adams-Campbell L, Bassford T, et al. 2001. Osteoporosis prevention, diagnosis, and therapy. JAMA, 285:785-95.
32. Kong YY, Feige U, Sarosi I, et al. 1999a. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 402:304-9.
33. Kong YY, Yoshida H, Sarosi I, et al. 1999b. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397:315-23.
34. Kostenuik PJ, Bolon B, Morony S, et al. 2004. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone, 34:656-64.
35. Kostenuik PJ, Capparelli C, Morony S, et al. 2001. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology, 142:4295-304.
36. Kostenuik PJ, Warmington K, Grisanti M, et al. 2005. RANKL inhibition with (denosumab) AMG 162, a fully human MAb, causes sustaned suppression of bone resorption and increased BMD in knockin mice expressing humanized RANKL. J Bone Miner Res, 20(Suppl 1):S261.
37. Lacey DL, Tan HL, Lu J, et al. 2000. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol, 157:435-48.
38. Lacey DL, Timms E, Tan HL, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93:165-76.
39. Lewiecki EM, Miller PD, McClung MR, et al. 2007. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res, 22:1832-41.
40. Li J, Sarosi I, Yan XQ, et al. 2000. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A, 97:1566-71.
41. Lipton A, Steger GG, Figueroa J, et al. 2007. Randomized active-controlled phase ii study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol, 25:4431-7.
42. Lobo, ED, Hansen, RJ, and Balthasar, JP. 2004. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci, 93(11):2645-68.
43. Matsuzaki K, Udagawa N, Takahashi N, et al. 1998. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun, 246:199-204.
44. McClung MR, Lewiecki EM, Cohen SB, et al. 2006. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med, 354:821-31.
45. McCombs JS, Thiebaud P, Laughlin-Miley C, et al. 2004. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas, 48:271-87.
46. Melton LJ III. 1995. How many women have osteoporosis now? J Bone Miner Res, 10:175-7.
47. Melton LJ III, Chrischilles EA, Cooper C, et al. 1992. Perspective. How many women have osteoporosis? J Bone Miner Res, 7:1005-10.
48. Miller PD, Bolognese MA, Lewiecki EM, et al. 2008. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone, 43:222-9.
49. Mosekilde L, Sogaard CH, Danielsen CC, et al. 1991. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology, 129:421-8.
50. Neumann E, Gay S, Muller-Ladner U. 2005. The RANK/RANKL/ osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis Rheum, 52:2960-7.
51. O'Brien EA, Williams JH, Marshall, MJ. 2000. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem Biophys Res Commun, 274:281-90.
52. O'Brien EA, Williams JH, Marshall, MJ. 2001. Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. Bone, 28:208-14.
53. Peterson MC, Stouch BJ, Martin SW, et al. 2005. The pharmacokinetics of denosumab (AMG 162) following various multiple subcutaneous dosing regimens in postmenopausal women with low bone mass. J Bone Miner Res, 20(Suppl 1):S293.
54. Redlich K, Hayer S, Maier A, et al. 2002. Tumor necrosis factor alphamediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum, 46:785-92.
55. Riggs BL, Parfitt, AM. 2005. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res, 20:177-84.
56. Ross AB, Bateman TA, Kostenuik PJ, et al. 2001. The effects of osteoprotegerin on the mechanical properties of rat bone. J Mater Sci Mater Med, 12:583-8.
57. Schett G, Redlich K, Hayer S, et al. 2003. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum, 48:2042-51.
58. Simonet WS, Lacey DL, Dunstan CR, et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89:309-19.
59. Solomon DH, Morris C, Cheng H, et al. 2005. Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc, 80:194-202.
60. Stilgren LS, Rettmer E, Eriksen EF, et al. 2004. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone, 35:256-65.
61. Stolina M, Dwyer D, Morony S, et al. 2005. Rats and mice overexpressing soluble OPG have high bone mass but no alteration in immunological parameters or lymphocyte function. Arthritis Rheum, (52):S708.
62. Stolina M, Dwyer D, Ominsky MS, et al. 2007. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J Immunol, 179:7497-505.
63. Tang L, Persky AM, Hochhaus G, et al. 2004. Pharmacokinetic aspects of biotechnology products. J Pharm Sci, 93:2184-204.
64. US Department of Health and Human Services. 2004. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD, US Department of Health and Human Services, Office of the Surgeon General.
65. Vanderkerken K, De LE, Shipman C, et al. 2003. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res, 63:287-9.
66. Whyte MP. 2006. The long and the short of bone therapy. N Engl J Med, 354:860-3.
67. Wong BR, Josien R, Lee SY, et al. 1997. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med, 186:2075-80.
68. Xing L, Schwarz EM, Boyce, BF. 2005. Osteoclast precursors, RANKL/ RANK, and immunology. Immunol Rev, 208:19-29.
69. Yood RA, Emani S, Reed JI, et al. 2003. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int, 14:965-8.